Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
Comorbidity documentation (when BMI is 35-39.9): At BMI 35-39.9, the record must identify at least one qualifying comorbidity such as type 2 diabetes, hypertension, sleep apnea, or severe musculoskeletal disease
GLP-1 medications address some of these challenges directly, which is part of why demand for semaglutide and tirzepatide has been particularly strong among adults in their 50s and 60s
The peptide is structurally derived from native human GLP-1(7-37) with two amino acid substitutions (Aib at position 8 for DPP-IV resistance, Arg substitution at position 34) and a C18 fatty diacid moiety conjugated via a Glu-(AEEA) linker enabling reversible albumin binding and an extended pharmacokinetic profile compatible with once-weekly dosing
Role of peripheral serotonin in glucose and lipid metabolism
In combination protocols, GHK-Cu is typically administered via subcutaneous injection at doses of 200 to 600 mcg daily
